What podcasts say about Stephen Hansen

Every statement, with the speaker, the exact quote and the moment it was said.

What Stephen Hansen has said on podcasts

7 statements · 3 positive · 3 negative · 1 mixed

on Public therapeutics company acquisitionsNegativeOct 13, 2026· BioCentury This Week
Large public therapeutics acquisitions have paused since mid-July.
“the last really big public therapeutics company acquisition was mid-July. It's been almost three months since then.”
Listen at 2:02
Open the episode · Ep. 392 - Biotech markets: Pause before the storm?
on ModernaPositiveOct 13, 2026· BioCentury This Week
Moderna reported positive Phase 3 adjuvant melanoma cancer data.
“the Moderna positive phase three cancer data in adjuvant melanoma”
Listen at 3:07
Open the episode · Ep. 392 - Biotech markets: Pause before the storm?
on Biotech market activityMixedOct 13, 2026· BioCentury This Week
Biotech activity will remain quiet in Q4 before recovering early next year.
“the thought is that it's going to be a pretty quiet fourth quarter as well and then hopefully things will pick up again at the start of the year”
Listen at 5:43
Open the episode · Ep. 392 - Biotech markets: Pause before the storm?
on Biotech reverse mergersPositiveOct 13, 2026· BioCentury This Week
IPO-capable biotech companies are increasingly choosing reverse mergers with large PIPE financings.
“We're seeing companies that easily could have done a traditional IPO, take the reverse merger route and raise really big pipes to go along with that.”
Listen at 7:09
Open the episode · Ep. 392 - Biotech markets: Pause before the storm?
on Biotech reverse mergers and PIPEsPositiveOct 13, 2026· BioCentury This Week
The biotech reverse-merger and PIPE trend will continue into Q4.
“I think there's every expectation that that will continue forward for sure into the fourth quarter.”
Listen at 7:21
Open the episode · Ep. 392 - Biotech markets: Pause before the storm?
on Biotech bond yieldsNegativeOct 13, 2026· BioCentury This Week
Higher bond yields pressure biotech valuations, financial models, and cost of capital.
“that can mess with valuations. It messes with models, but, you know, cost of capital.”
Listen at 8:05
Open the episode · Ep. 392 - Biotech markets: Pause before the storm?
on Biotech IPOsNegativeOct 13, 2026· BioCentury This Week
Recent weak IPO performance may cause prospective biotech issuers to delay listings.
“the performance by those last two might give people pause”
Listen at 10:03
Open the episode · Ep. 392 - Biotech markets: Pause before the storm?

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.